Our site uses cookies, view our cookie policy. To view the site without this banner, you must accept our cookie usage.

Photograph of Dr. Christopher Boos

Our Staff

Dr Christopher J Boos

GMC number: 4106845


Cardiology and General Internal Medicine


Heart Failure Specialist 

Cardiac Device Specialist (including cardiac resynchronisation therapy [CRT] and implantable cardiac defibrillators [ICD])

Sports Cardiology and cardiopulmonary exercise testing (CPX, CPET, CPEX) and Medico legal work


Other interests: atrial fibrillation, high altitude medicine, breathlessness and cardiomyopathies


  • MB BS, St Mary's Hospital Medical School, London, 1994

  • Dip IMC RCS Royal College of Surgeons of Edinburgh, 1997

  • MD - Doctor of Medicine, University of Birmingham, 2007

  • FRCP, Royal College of Physicians of London, 2011


After qualifying at St Mary's Hospital in London in 1994, I undertook junior hospital appointments in London (St Mary's Hospital, Royal London and Royal Brompton Hospitals) and Portsmouth (Queen Alexandra, St Mary's and Haslar Hospitals). Thereafter, I commenced my Cardiology training initially in the Wessex region where I worked in Salisbury (one year), Portsmouth (two years) and Southampton General Hospitals (one year) respectively. I then transferred to the Birmingham Deanery after to do a two year Research Doctorate (MD) at City Hospital. Subsequently, I then completed my final 18 months of Cardiology training at University Hospital Birmingham, prior to moving to Poole as a Consultant Cardiologist.

My current NHS employment is at both Poole and the Royal Bournemouth with additional private sessions at these hospitals and at the Harbour Hospital in Poole.


Original Articles

  • Boos C, Wilbourne G, Clarke E et al. Higher energy monophasic direct current cardioversion for persistent atrial fibrillation: is it time to start at 360 joules? Annals of Non Invasive Electrocardiology 2003;8:121-127.

  • Boos C and Croft A. Smoking rates in the staff of a military field hospital before and after wartime deployment. J R Soc Med 2004;97:20-22.

  • Boos C, Ritzema J and More R. Short burst oral amiodarone improves cardioversion success rates for patients in persistent atrial fibrillation. Heart 2004 2004;90:1063-4.

  • Boos CJ, Gough S, Wheater M et al. The Effects of Transvenous Pacing on Cardiac Troponin Release. Pacing Clin Electrophysiol 2004;27:1264-1268.

  • Bailey MS, Boos CJ, Vautier G et al. Gastroenteritis outbreak in British troops, Iraq. Emerg Infect Dis 2005;11:1625-8.

  • Boos CJ, Lane DA, Kang D et al. Temporal and venepuncture-related decline in Circulating Endothelial Cell capture from mixed venous blood. J Thromb Thrombolysis 2006;22:125-31.

  • Goon PKY, Boos CJ, Stonelake PS et al. Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads:  a methodological comparison. Thromb Haemostas 2006;96:45-52.

  • Boos CJ, Jaumdally RJ, Macfayden RJ et al. Circulating endothelial cells and von Willebrand factor as indices of endothelial damage/dysfunction in coronary artery disease: a comparison of central vs peripheral levels and effects of coronary angioplasty. J Thromb Haemost 2007;5:630-2. 

  • Boos CJ, Beevers G, Lip GYH. Assessment of platelet activation indices using the ADVIATM120 amongst ‘high risk’ patients with hypertension. Ann Med 2007;39:72-8. 

  • Boos CJ, Mayr FB, Lip GY et al. Endotoxemia enhances circulating endothelial cells in humans. J Thromb Haemost 2006;4:2509-11.

  • Boos CJ, Soor SK, Kang D et al. Relationship between Circulating Endothelial Cells and the predicted risk of Cardiovascular Events in Acute Coronary Syndromes. European Heart Journal 2007;28:1092-101. 

  • Goon PK, Watson T, Shantsila E, Boos CJ and Lip GY. Standardization of circulating endothelial cell enumeration by the use of human umbilical vein endothelial cells. J Thromb Haemost 2007;5:870-2. 

  • Boos CJ, Balakrishnan B and Lip GY. The effects of exercise stress testing on soluble E-selectin, von Willebrand factor, and circulating endothelial cells as indices of endothelial damage/dysfunction. Ann Med 2008;40:66-73. 

  • Boos CJ, Lip GY and Jilma B. Endotoxemia, inflammation, and atrial fibrillation. Am J Cardiol 2007;100:986-8. 

  • Boos CJ, Balakrishnan B and Lip GY. The effects of coronary artery disease severity on time-dependent change in platelet activation indices in stored whole blood. J Thromb Thrombolysis 2008;25:135-40. 

  • Boos CJ, Lane DA, Karpha M et al. Circulating endothelial cells, arterial stiffness and cardiovascular risk stratification in hypertension. Chest 2007;132:1540-7. 

  • Boos CJ, Balakrishnan B, Jessani S, Blann AD, Lip GY. Effects of percutaneous coronary intervention on peripheral venous blood circulating endothelial cells and plasma indices of endothelial damage/dysfunction. Chest 2007;132:1920-6. 

  • Boos CJ, Balakrishnan B, Blann AD, Lip GY. The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis. J Thromb Haemos. 2008;6:1841-50. 

  • Boos CJ, Wheble GA, Campbell MJ, Tabner KC, Woods DR.Self-administration of exercise and dietary supplements in deployed British military personnel during Operation TELIC 13. J R Army Med Corps 2010;156:32-6. 

  • Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, Boos CJ, Xing W, Egan C, Peto T, Bunce C, Leslie RD, Hykin PG. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117:1078.

  • Idriss NK, Lip GY, Balakrishnan B, Jaumdally R, Boos CJ, Blann AD. Plasma haemoxygenase-1 in coronary artery disease. A comparison with angiogenin, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and vascular endothelial growth factor. Thromb Haemost 2010;104:1029-37.


Review Articles

  • Boos C and More R. Rate control in atrial fibrillation. Clinical Medicine 2003;3:291-2.

  • Boos C and More R. Management of Persistent Atrial Fibrillation in the Older Patient. Geriatric Medicine 2003;33:51-7.

  • Carlsson J and Boos C. Confounding factors in rate versus rhythm control trials in patients with atrial fibrillation: Lessons from the Strategies of Treatment of Atrial Fibrillation (STAF) Pilot Study. Card Electrophysiol Rev 2003;7:122-6.

  • Boos C, Carlsson J and More R. Rate or rhythm control in persistent atrial fibrillation, Quarterly Journal of Medicine 2003;96:881-92.

  • Boos CJ and More R. Anticoagulation for non-valvular atrial fibrillation - towards a new beginning with ximelagatran. Curr Control Trials Cardiovasc Med 2004;5:3.

  • Boos CJ and Lip GYK. Novel therapies for the prevention of stroke. Expert Opin Investig Drugs 2004;13:1615-30.

  • Boos CJ ACE Cardiovascular protection. More HOPE for EUROPA Med Sci Monit 2004;10:SR23-28.

  • Boos CJ, Hinton A and Lip GYH Ximelagatran: a clinical perspective. Eur J Intern Med 2005; 16:267-78.

  • Boos CJ and Lip GYH Blood clotting, inflammation, and thrombosis in cardiovascular events: perspectives. Front Biosc 2006;11:328-36.

  • Boos CJ and Lip GYH Ximelagatran for stroke prevention in atrial fibrillation. Expert Rev Cardiovasc Ther 2005;3:551-63.

  • Goon PKY, Boos CJ and Lip GYH Circulating Endothelial Cells: markers of vascular dysfunction. Clin Lab 2005;51:531-8.

  • Boos CJ and Lip GYH Is hypertension an inflammatory process. Curr Pharm Des 2006;12:1623-1635.

  • Boos CJ and Lip GYH Antithrombotic treatment in atrial fibrillation. Heart 2006;92:155-61.

  • Boos CJ, Anderson RA and Lip GYH Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006;27:136-49.

  • Boos CJ and Lip GYH Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials. J Hum Hypertens 2005;19:855-9

  • Goon PKY, Boos CJ and Lip GYH Circulating endothelial cells in malignant disease. Future Oncology 2005;1:813-20.

  • Goon PKY, Boos CJ and Lip GYH Circulating endothelial cells and circulating endothelial progenitor cells in cancer. Neoplasia 2006;8:79-88.

  • Boos CJ, Lip GY and Blann AD Circulating endothelial cells in cardiovascular disease. J Am Coll Cardiol 2006;48:1538-47.

  • Boos CJ and Lip GY Assessment of mean platelet volume in coronary artery disease - What does it mean? Thromb Res 2007;120:11-3.

  • Boos CJ, Lane D and Lip GYH Management of chronic atrial fibrillation. Clin Evidence (BMJ) 2007

  • Kakar P, Boos CJ and Lip GY Management of atrial fibrillation. Vasc Health Risk Manag 2007;3:109-16.

  • Boos CJ, Blann AD and Lip GY. Assessment of endothelial damage/dysfunction: a focus on circulating endothelial cells. Methods Mol Med 2007;139:211-24.

  • Lip GYH, Boos CJ Antithrombotic treatment in atrial fibrillation. Postgrad Med J 2008;84:252-8.

  • Boos CJ, Blann AD, Lip GY Assessment of endothelial damage/dysfunction: a focus on circulating endothelial cells. Methods Mol Med 2007;139:211.


    Boos CJ, Cox AT. Cardiology. J R Army Med Corps 2010;156:172-5.


    Woods DR, Boos C, Roberts PR. Cardiac arrhythmias at high altitude. J R Army Med Corps 2011;157:59-62





  • Boos C, Carlsson J and More R Persistent atrial fibrillation. Rate control or rhythm control. Rate control is not inferior to rhythm control. BMJ 2003;326:1411-12.

  • Boos CJ and Dawes M ACE cardiovascular protection: EUROPA versus HOPE. Cardiovascular Drugs and Therapy 2004;18:179-180.

  • Boos CJ and Lip GYH Elevated high-sensitive C-reactive protein, large arterial stiffness and atherosclerosis: a relationship between inflammation and hypertension? J Hum Hypertens 2005;19:511-3.

  • Boos CJ and Lip GYH The role of inflammation in atrial fibrillation. Int J Clin Pract 2005;59:870-2.

  • Lip GYH and Boos CJ Ethnic differences in arterial responses, inflammation, and metabolic profiles: possible insights into ethnic differences in cardiovascular disease and stroke. Arterioscler Thromb Vasc Biol 2005;25:2240-2.

  • Boos CJ and Lip GYH Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events. Arterioscler Thromb Vasc Biol 2006;26:e18.

  • Boos CJ, Goon PKY and Lip GYH The endothelium, inflammation and coagulation in sepsis. Clin Pharmacol Ther 2006;79:20-2.

  • Boos CJ, Goon PK and Lip GY Endothelial progenitor cells in the vascular pathophysiology of hypertension: arterial stiffness, ageing and more. J Hum Hypertens 2006;20:475-7.

  • Boos CJ and Lip GYH Ximelagatran – a eulogy. Throm Res 2006;118:301-4.

  • Lane DA, Boos CJ and Lip GYH Anticoagulation control with vitamin K antagonists- how well are we doing? Chest 2006;129:1122-4.

  • Boos CJ and Lip GYH Urotensin and cardiovascular risk among patients with end-stage renal disease: fact or fiction? Am J Hypertens 2006;19:511-2.

  • Boos CJ and Lip GY Platelet activation and cardiovascular outcomes in acute coronary syndromes. J Thromb Haemost 2006;4:2542-3.

  • Boos CJ, Lip GY C-reactive protein and lone atrial fibrillation: potential confounders.Am J Cardiol 2006;98:991-2.

  • Boos CJ and Lip GY. Inflammation and atrial fibrillation: cause or effect? Heart 2008;94:133-4.


Case Reports

  • Boos CJ Keloid scarring in a soldier secondary to military cap badge branding. Update 1997;654.

  • Boos C and Matfin G Klinefelter's Syndrome manifesting as an acute pulmonary embolus in a 52 year old man. Endocrine Practice 2002;8:68-9.

  • Boos C, Rumsby G and Matfin G Multiple tumors associated with late onset congenital adrenal hyperplasia due to aberrant splicing of adrenal 21-hydroxylase gene. Endocrine Practice 2003;8:470-3.

  • Boos C, Dawes M, Jones R et al T. Danazol treatment and acute myocardial infarction. Journal of Obstetrics and Gynaecology 2003;23:327-8.

  • Boos C, Allen P, More R et al Fever six weeks after trauma. Journal of the Royal Society of Medicine 2003;96:187-8.

  • CJ Boos, P Flies, M Dawes et al Shortness of breath in an obese young man. Journal of Academic Physician Assistants 2003;3:2.

  • Boos CJ, Daneshvar C, Hinton A et al An unusual case of chronic meningitis. BMC Fam Pract 2004;5:21.

  • Boos CJ, Calver AL, Moors A et al Uterine artery embolisation in the setting of acute submassive pulmonary embolism. BJOG 2005;112:1440-2.

  • Boos CJ, Khan Y and Throne S An unusual case of misdiagnosed ventricular tachycardia. Emerg Med J 2008;25:173-4.

  • Boos CJ, Bentall AJ, Marshall HJ A technique to overcome high defibrillation thresholds for an implantable cardioverter defibrillator Cardiol Young 2009;19:291.

  • Boos CJ, Martin U, Cherry RC, Marshall HJ. Dangerous Sanwiches. Lancet 2008;372:2164.

  • Boos CJ, White SH, Bland SA, McAllister PD.  Dietary supplements and military operations: caution is advised.  J R Army Med Corp 2010;156:41-3.

  • White SH, Dickson S, Colman T, Hoque F, Boos CJ. Back pain in a Bangladeshi worker in Iraq. J R Army Med Corps 2010;156:44-6 .



  • Boos CJ Present treatment options for atrial fibrillation. Postgrad Med J 2003;79:604.

  • Boos CJ Atrial fibrillation. Cleve Clin J Med 2003;70:998.

  • Boos CJ Oral anticoagulation and stroke in atrial fibrillation. N Engl J Med 2003;349:2360-1.

  • Boos CJ The EUROPA trial. Lancet 2003;362:1935.

  • Boos CJ Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004;25:1761.

  • Boos CJ, Lip GYH Biomarkers in atrial fibrillation: further observations on biologic plausibility, cause and effect Journal of Thrombosis and Thrombolysis 2005;20:189-90.

  • Boos CJ, Lip GYH Prevention of Atrial fibrillation by Angiotensin-Converting-Enzyme inhibitors and Angiotensin II receptor blockers: some pathophysiological insights. J Am Coll Cardio 2006;47:889-90.

  • Boos CJ, Goon PKY and Lip GYH Circulating endothelial progenitor cells. N Engl J Med 2005;353:2613.

  • Boos CJ and Lip GYH Assessment of Hemostatic Risk Factors in Predicting Arterial thrombotic Events.  ATVB 2006;26:e18.

  • Boos CJ and Lip GYH The role of inflammation in atrial fibrillation: Increasing Evidence in support of a novel concept. In J Clin Pract 2006; 60:497-8.

  • Boos CJ and Lip GYH Is atrial fibrillation an inflammatory disorder?  Responses and clarifications. European Heart Journal 2006;27:136-49.

  • Boos CJ and Marshall HJ Risk of thromboembolism and bleeding with short-term interruption of anticoagulant therapy. Arch Intern Med 2008;168:1932.

  • Gorman S, Boos C Ivabradine in heart failure: what about digoxin? Lancet 2008;372:2113.

Book Chapters

  • Boos CJ and Lip GYH Assessment of endothelial damage/dysfunction: a focus on circulating endothelial cells. Vascular Biology Protocols 2006.

  • Boos CJ and Lip GYH Insights into novel anticoagulants. Thrombosis Molecular Mechanisms of Disease 2006.